NeRRe Therapeutics, which is developing a portfolio of neurokinin (NK)-1 receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity, has appointed Andrew Kay as Chairman of the Board. Andrew has worked in the biotechnology sector as CEO of Algeta, which was sold to Bayer for $2.9bn in 2014, and as Chief Commercial Officer and a Board Director of Renovo. He started his industry career in the pharmaceutical sector, working in international roles at Novartis, AstraZeneca and Eli Lilly.
